SCHEMBL7979638

SCHEMBL7979638

CC(CN1CCOCC1)C(N)=O

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.68
LMNA P02545 1/20 0.54
KDM4E B2RXH2 4/20 0.52
USP2 O75604 1/20 0.50
ANPEP P15144 1/20 0.49
NPC1 O15118 1/20 0.43
HSD17B10 Q99714 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
ALOX12 P18054 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9512804 0.84 ALDH1A1 (0.72) ALDH1A1LMNAKDM4EUSP2ANPEP
SCHEMBL14276784 0.82 ALDH1A1 (0.70) ALDH1A1LMNAKDM4EUSP2ANPEP
SCHEMBL500091 0.82 ALDH1A1 (0.96) ALDH1A1LMNAKDM4EUSP2ANPEP
SCHEMBL30017355 0.82 CHRM2 (0.49) ALDH1A1LMNAANPEPHSD17B10L3MBTL1
SCHEMBL4405073 0.81 ALDH1A1 (0.50) ALDH1A1LMNAKDM4ETSHRGLA
SCHEMBL14562932 0.81 ALDH1A1 (0.50) ALDH1A1LMNAKDM4ETSHRGLA
SCHEMBL27899777 0.81 ALDH1A1 (0.93) ALDH1A1LMNAKDM4EUSP2ANPEP
SCHEMBL7979632 0.81 ALDH1A1 (0.68) ALDH1A1LMNAKDM4EUSP2ANPEP
SCHEMBL17730414 0.80 ALDH1A1 (0.62) ALDH1A1LMNAKDM4EUSP2ANPEP
SCHEMBL21748901 0.80 CHRM2 (0.51) ALDH1A1LMNAUSP2ANPEPHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012467-B2 Small molecule DCN1 inhibitors and therapeutic methods using the same REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-06-18 US disclosed
US-20200109167-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2020-04-09 US disclosed
EP-3215505-B1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE Bayer Pharma AG (DE) 2019-07-24 EP disclosed
CN-1774435-A 5-membered heterocyclic derivative DAIICHI SEIYAKU CO (JP) 2006-05-17 CN disclosed
CN-1759110-A Pyrazole derivatives DAIICHI SEIYAKU CO (JP) 2006-04-12 CN disclosed
WO-2001007409-A1 CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS ASTRAZENECA UK LIMITED (GB) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109167-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME DCUN1D2, CLN6, CAPNS1 ALDH1A1 2290/4885LMNA 392/4885KDM4E 4008/4885
US-12012467-B2 Small molecule DCN1 inhibitors and therapeutic methods using the same DCUN1D2, CLN6, CAPNS1 ALDH1A1 2290/4885LMNA 392/4885KDM4E 4008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.